Thus, these data suggest a role for CaV3.1 in co-regulating sleep and weight maintenance and data from pharmacological studies demonstrate that potent and selective T-type calcium channel antagonists reduce– wakefulness, diet-induced weight gain, and improve- body composition, suggesting this ion channel class may provide a novel therapeutic target for the treatment of obesity. Here, CACNA1G is linked to Obesity.